Announcements

The company has acquired ordinary shares of Obigen Pharma, Inc.

1. Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.): ordinary shares of Obigen Pharma, …

The company will postpone the annual shareholders’ meeting to June 21, 2021 in accordance with the instructions of FSC (distribution of electronic voting shareholders’ complimentary gift)

1. Date of occurrence: May 24, 2021 2. Due to “Measures for public companies to postpone shareholders’ meetings for pandemic prevention”, the Company suspended the convening of a shareholders’ meetings …

The Company will postpone the Annual Shareholders’ meeting on June 21, 2021 in accordance with the instructions of FSC

1. Date of occurrence: May 20, 2021 2. Due to “Measures for public companies to postpone shareholders’ meetings for pandemic prevention”, the Company suspended the convening of a shareholders’ meetings …

Supplementary statement for 2021 shareholders’ meeting (change of location)

1. Date of the board of directors’ resolution: May 19, 2021 2. General shareholders’ meeting date: Jun 21, 2021 3. General shareholders’ meeting location: Courtyard Taipei, 7F Supernova Ballroom (7F, …

OBI-999 completes its Phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to Phase 2 as planned

1. Date of occurrence of the event: May 13, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …

Supplementary statement for 2021 shareholders’ meeting (additional matters)

1. Date of the board of directors’ resolution: May 7, 2021 2. General shareholders’ meeting date: Jun 21, 2021 3. General shareholders’ meeting location: Masterlink Securities Education and Training Center …

Announcement that the consolidated financial statements for the first quarter of 2021 were authorized for issuance by the Board of Directors

1. Date of the financial reports submitted to the board of directors or approved by the board of directors: May 7, 2021 2. Date of the financial reports approved by …

Updates on the planned allocation of the cash raised from the 2018 fundraising

1. Date of the board of directors resolution for the change: May 7, 2021 2. Effective registration date of the original plan: Mar 25, 2019 3. Major change Reason for …

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study

1. Date of occurrence of the event: May 6, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …

OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned

1. Date of occurrence of the event: May 5, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …